Ligand第三季度版税收入7,030万美元同比增51% 调整后每股收益2.67美元、全年指引上调至9.50至9.75美元
生物制药版税聚合商 Ligand Pharmaceuticals Incorporated（Nasdaq: LGND）10月29日公布2026年第三季度业绩：版税收入7,030万美元，较去年同期的4,660万美元增长51%，占当季总收入的89%。
增长主要来自新收购的 XOMA 资产组合，以及 Travere Therapeutics 的 Filspari 与 Merck 的 Ohtuvayre 等核心商业资产的持续动能。当季总收入与收益为7,870万美元，去年同期为1.155亿美元；去年同期包含与 Pelthos 剥离相关的5,310万美元收入，剔除该项后总收入同比增长26%。Captisol 销售790万美元，去年同期为1,070万美元。
按美国通用会计准则（GAAP）计算，当季净亏损2,850万美元、每股亏损1.43美元，去年同期为净利1.173亿美元；调整后净利为5,750万美元、调整后摊薄每股收益2.67美元，去年同期分别为6,380万美元与3.09美元。
首席执行官 Todd Davis 表示，公司当季再交强劲业绩，版税收入同比增长51%，并继续把资本投向差异化资产，包括收购 Santen 的 Ryjunea 版税权益，以及与 AvenCell Therapeutics 达成结构性融资协议以推进其下一代 CAR-T 管线。
截至9月30日，公司现金、现金等价物与短期投资合计4.474亿美元；计入股权投资与信贷额度可用量，可部署资本约7.5亿美元。公司上调2026年全年调整后摊薄每股收益指引至9.50至9.75美元（原为9.00至9.50美元），并重申全年总收入指引2.70亿至3.10亿美元。Ligand 总部位于佛罗里达州 Jupiter，今年7月完成对 XOMA Royalty 的收购后，其版税组合已扩至逾200项商业、临床与临床前资产。
Ligand Q3 Royalty Revenue Jumps 51% to $70.3 Million, Adjusted EPS $2.67 as Full-Year Guidance Is Raised to $9.50-$9.75
Royalty aggregator Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) on October 29 reported results for the third quarter of 2026. Royalty revenue rose 51% year over year to $70.3 million, from $46.6 million, and accounted for 89% of total revenues and income in the quarter.
Growth was driven by the newly acquired XOMA assets and continued momentum across the company's key commercial portfolio, including Travere Therapeutics' Filspari and Merck's Ohtuvayre. Total revenues and income were $78.7 million, compared with $115.5 million a year earlier, a period that included $53.1 million of Pelthos divestiture-related income; excluding that income, total revenues and income increased 26%. Captisol sales were $7.9 million, compared with $10.7 million a year earlier.
On a GAAP basis, the company posted a net loss of $28.5 million, or $1.43 per share, compared with net income of $117.3 million a year earlier. Adjusted net income was $57.5 million, or $2.67 per diluted share, compared with $63.8 million, or $3.09, a year earlier.
Chief Executive Officer Todd Davis said Ligand delivered another strong quarter, with royalty revenue growing 51% year over year, and that the company continued to put capital to work in differentiated assets, acquiring a royalty interest in Santen's Ryjunea and entering a structured financing agreement with AvenCell Therapeutics to advance its next-generation CAR-T pipeline.
As of September 30, Ligand held cash, cash equivalents and short-term investments of $447.4 million, with approximately $750 million of deployable capital including equity investments and credit facility availability. The company raised its full-year 2026 adjusted diluted EPS guidance to $9.50 to $9.75, from $9.00 to $9.50, and reaffirmed total revenue guidance of $270 million to $310 million. Headquartered in Jupiter, Florida, Ligand completed its acquisition of XOMA Royalty in July, more than doubling its portfolio to over 200 commercial, clinical and preclinical royalty assets.
来源：GSM·美国（原文链接）
图片来源：图：实验室工作台上的移液器与样本管（资料图）。Goldmund100 摄，CC BY-SA 3.0，经 Wikimedia Commons。 / Pipettes and sample tubes on a laboratory bench (file photo). Photo by Goldmund100, CC BY-SA 3.0, via Wikimedia Commons.
